# A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients

> **NCT01726348** · — · WITHDRAWN · sponsor: **Janssen Pharmaceutica**

## Conditions studied

- Human Immunodeficiency Virus-Type 1

## Interventions

- **DRUG:** No intervention

## Key facts

- **NCT ID:** NCT01726348
- **Lead sponsor:** Janssen Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-01
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The company decided to cancel this study in conformity with PH FDA Circular 2013-004
- **Last updated:** 2015-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01726348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01726348, "A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01726348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*